Sildenafil's primary molecular target is phosphodiesterase type 5, or PDE5, a cGMP-specific phosphodiesterase that hydrolyzes cyclic GMP and helps terminate cGMP-dependent signaling. Sildenafil inhibits this enzyme rather than directly generating nitric oxide or cGMP.
Classic in-vitro pharmacology characterized sildenafil as a potent competitive PDE5 inhibitor, with an IC50 of approximately 3.5 nM under the reported assay conditions. Current U.S. labeling also shows that the drug is strongly selective for PDE5 relative to most other phosphodiesterases, although selectivity is substantially narrower for retinal PDE6.
This page focuses on the target-level mechanism, competitive inhibition and phosphodiesterase selectivity. The complete upstream and downstream signaling chain belongs on the sildenafil NO–cGMP pathway page, while exposure-response and physiological outcomes belong on the sildenafil pharmacodynamics page.
PDE5 is a cyclic nucleotide phosphodiesterase with a strong functional preference for cGMP. Its catalytic activity hydrolyzes cGMP to 5′-GMP, reducing intracellular cGMP concentrations and helping terminate or limit cGMP-mediated signaling.
PDE5 is especially relevant to sildenafil pharmacology in corpus cavernosum smooth muscle and pulmonary vascular smooth muscle, but current labeling also identifies PDE5 in vascular and visceral smooth muscle and platelets, with additional tissue expression reported elsewhere.
PDE5 therefore acts as a signal-regulation enzyme rather than as the source of the NO–cGMP signal. Sildenafil changes pathway behavior by inhibiting this regulatory step.
| PDE5 Feature | Pharmacologic Meaning |
|---|---|
| Enzyme family | Phosphodiesterase |
| Major substrate | cGMP |
| Catalytic reaction | Hydrolysis of cGMP to 5′-GMP |
| Signaling role | Limits cGMP concentration and signal persistence |
| Key sildenafil target tissues | Corpus cavernosum and pulmonary vascular smooth muscle |
| Sildenafil action | Inhibits PDE5 catalytic activity |
Sildenafil acts as a competitive inhibitor of PDE5. It interacts with the enzyme's catalytic substrate-binding region and reduces the ability of PDE5 to hydrolyze cGMP.
In the classic preclinical pharmacology characterization, sildenafil inhibited PDE5 with an IC50 of approximately 3.5 nM. That number describes potency under specific in-vitro assay conditions and should not be interpreted as a plasma concentration threshold that guarantees a particular clinical response.
When sildenafil occupies PDE5, enzymatic degradation of cGMP decreases. The immediate molecular consequence is therefore preservation of cGMP rather than direct activation of nitric oxide synthase or guanylate cyclase.
Target inhibition becomes biologically relevant only when cGMP is being generated through an active upstream pathway.
| Mechanistic Step | Sildenafil-Specific Interpretation |
|---|---|
| Drug reaches PDE5 | Sildenafil becomes available to interact with the enzyme |
| Competitive inhibition | Sildenafil interferes with PDE5 catalytic processing of cGMP |
| In-vitro potency | IC50 approximately 3.5 nM in a classic PDE5 assay |
| Immediate molecular consequence | Reduced cGMP hydrolysis |
| Downstream consequence | Greater persistence of cGMP-dependent signaling when upstream signaling is active |
PDE5 provides one of the principal enzymatic routes for terminating cGMP signaling in tissues where it is expressed. It hydrolyzes cGMP after that second messenger has been generated through upstream signaling.
Sildenafil reduces this hydrolysis. The result is an increase in the amount or persistence of cGMP relative to the state in which PDE5 remains uninhibited.
This mechanism is dependent on cGMP generation. Sildenafil does not manufacture cGMP; it changes its rate of enzymatic removal. The full sequence from nitric oxide through soluble guanylate cyclase, cGMP and downstream PKG signaling is covered on the NO–cGMP pathway page.
| State | PDE5 Activity | Effect on cGMP |
|---|---|---|
| Upstream signaling active, no sildenafil | PDE5 continues hydrolysis | cGMP is produced and continuously degraded |
| Sildenafil reaches PDE5 | Catalytic activity is inhibited | cGMP degradation decreases |
| Net signaling effect | PDE5-mediated termination is reduced | cGMP signaling can persist more strongly |
| No upstream cGMP generation | PDE5 may still be inhibited | Sildenafil does not independently create the upstream signal |
Sildenafil is sometimes described too loosely as though it directly creates the downstream physiological response. At the molecular level, its action is narrower: it inhibits an enzyme responsible for terminating cGMP signaling.
In the erectile-dysfunction context, current labeling states that sildenafil has no direct relaxant effect on isolated human corpus cavernosum. Sexual stimulation produces local nitric oxide release, and sildenafil then enhances the resulting cGMP signal by inhibiting PDE5.
This dependence on upstream activity is fundamental to target-level interpretation. Enzyme inhibition can amplify or preserve a signal that exists, but it does not replace the biological process that generates that signal.
| Possible Description | Accurate for Sildenafil? |
|---|---|
| Direct nitric oxide generator | No |
| Direct guanylate cyclase activator | No |
| Direct cGMP producer | No |
| Competitive PDE5 inhibitor | Yes |
| Reducer of PDE5-mediated cGMP degradation | Yes |
| Enhancer of an existing NO–cGMP signal | Yes |
Sildenafil is selective for PDE5, but selectivity is relative rather than absolute. Current U.S. labeling compares its potency at PDE5 with multiple related phosphodiesterase isoforms.
The narrowest labeled separation is between PDE5 and PDE6: sildenafil is only about 10-fold more potent at PDE5. PDE6 is expressed in the retina and participates in phototransduction, making this comparatively modest selectivity pharmacologically important.
The separation is much larger for most other phosphodiesterases. Labeling reports greater than 80-fold selectivity over PDE1 and greater than 700-fold selectivity over PDE2, PDE3, PDE4 and PDE7 through PDE11, with an approximately 4,000-fold difference versus PDE3 specifically.
These are in-vitro relative-potency comparisons. They should not be interpreted as dose-conversion ratios or as exact predictions of target occupancy in an individual.
| Comparison | Approximate PDE5 Selectivity | Why It Matters |
|---|---|---|
| PDE5 vs PDE6 | About 10-fold | PDE6 participates in retinal phototransduction |
| PDE5 vs PDE1 | Greater than 80-fold | Shows substantially stronger preference for PDE5 |
| PDE5 vs PDE2 | Greater than 700-fold | High in-vitro target separation |
| PDE5 vs PDE3 | Approximately 4,000-fold | PDE3 participates in cardiac contractility |
| PDE5 vs PDE4 | Greater than 700-fold | High in-vitro target separation |
| PDE5 vs PDE7–PDE11 | Greater than 700-fold | High in-vitro target separation |
Phosphodiesterases are a broader enzyme family that regulates cyclic nucleotide signaling. Different PDE families differ in substrate preference, tissue distribution, regulatory properties and physiological function.
Sildenafil's pharmacological profile reflects a strong preference for PDE5 rather than uniform inhibition of all phosphodiesterases. That distinction is why the numerical selectivity profile matters.
PDE6 is a particularly important neighboring target because it is involved in retinal phototransduction. PDE3 is important for a different reason: it contributes to regulation of cardiac contractility, while sildenafil is approximately 4,000-fold more selective for PDE5 than PDE3.
| PDE | Relevant Context for Sildenafil |
|---|---|
| PDE5 | Primary target; cGMP hydrolysis |
| PDE6 | Retinal phototransduction; closest major labeled selectivity comparison |
| PDE1 | Much lower sildenafil potency than PDE5 |
| PDE3 | Involved in cardiac contractility; very large selectivity margin versus PDE5 |
| Other labeled PDE comparisons | PDE2, PDE4 and PDE7–PDE11 show substantially lower in-vitro sensitivity than PDE5 |
An in-vitro potency value such as IC50 characterizes an experimental enzyme system; pharmacokinetic exposure describes sildenafil concentrations in plasma across time. These measurements answer different questions.
Higher systemic exposure can increase the opportunity for sildenafil to reach and inhibit PDE5, but plasma concentration cannot be converted directly into an exact percentage of PDE5 inhibition in a person. Tissue distribution, free drug concentration, target availability and biological context all matter.
Current ED pharmacodynamic studies nevertheless show that erectile response generally increased with increasing sildenafil dose and plasma concentration. That represents an exposure-response relationship, not a simple equivalence between plasma concentration and target occupancy.
The PK side is covered on the sildenafil exposure page, while integrated exposure-response interpretation belongs on the sildenafil pharmacodynamics page.
| Measure | What It Describes |
|---|---|
| In-vitro IC50 | Concentration producing 50% inhibition under a defined experimental assay |
| Plasma concentration | Systemic drug concentration measured in vivo |
| Target-site exposure | Drug available to interact with PDE5 in tissue |
| Target inhibition | Functional reduction in PDE5 activity |
| Observed response | Integrated downstream pharmacodynamic outcome |
PDE5 inhibition changes over time as sildenafil concentrations rise and fall. The target-level time course therefore depends partly on absorption, distribution and elimination.
Peak plasma concentration does not define a unique moment of maximum clinical effect. PDE5 can already be inhibited while concentrations are rising, and downstream response also depends on pathway activation rather than plasma concentration alone.
Similarly, the approximately 4-hour terminal sildenafil half-life does not mean PDE5 inhibition begins or ends at one fixed four-hour boundary. PK parameters provide exposure context, while the PD response has its own time course.
Clinical timing is handled separately on the sildenafil onset page and sildenafil duration page.
| Timing Measure | Interpretation |
|---|---|
| Tmax | Time of observed plasma concentration peak |
| Cmax | Peak measured plasma concentration |
| PDE5 inhibition | Target-level process that changes as target-site exposure changes |
| Clinical onset | Beginning of an observed response under defined conditions |
| Terminal half-life | Later concentration-decline parameter, not an on/off timer for PDE5 inhibition |
N-desmethyl sildenafil is the major circulating active metabolite and retains a phosphodiesterase selectivity profile similar to the parent compound.
Current labeling reports that its in-vitro PDE5 potency is approximately 50% of parent sildenafil. In healthy volunteers, metabolite plasma concentrations are approximately 40% of parent concentrations, leading labeling to estimate an approximately 20% contribution to sildenafil's overall pharmacologic effects.
The metabolite therefore adds to total PDE5-inhibitory pharmacology without being equivalent to parent sildenafil molecule-for-molecule. Its formation, concentration-time profile and elimination remain on the sildenafil active metabolite page.
| Component | PDE5 Context |
|---|---|
| Parent sildenafil | Primary administered PDE5 inhibitor |
| N-desmethyl sildenafil | Major circulating active metabolite |
| Metabolite PDE selectivity | Similar general profile to parent sildenafil |
| Metabolite in-vitro PDE5 potency | Approximately 50% of parent |
| Healthy-volunteer plasma concentration | Approximately 40% of parent concentration |
| Estimated pharmacologic contribution | Approximately 20% |
| Detailed resource | Sildenafil Active Metabolite |
PDE5 inhibition is sildenafil's primary target-level pharmacodynamic event, but it sits inside a larger sequence rather than constituting the complete pharmacodynamic response.
Upstream nitric oxide activates soluble guanylate cyclase and increases cGMP formation. Sildenafil reduces PDE5-mediated degradation of that cGMP. Downstream cGMP-dependent signaling then alters smooth-muscle regulation.
This page deliberately stops at the target and selectivity level. The sildenafil NO–cGMP pathway page covers the complete molecular signaling sequence, while the sildenafil pharmacodynamics page connects mechanism with measurable biological response.
| Mechanistic Level | Primary Topic | Dedicated Resource |
|---|---|---|
| Target | PDE5 inhibition and selectivity | Current page |
| Signal generation | NO and guanylate cyclase | Sildenafil NO–cGMP Pathway |
| Second-messenger regulation | cGMP formation and degradation | Sildenafil NO–cGMP Pathway |
| Integrated response | Exposure, target action and biological effect | Sildenafil Pharmacodynamics |
Selectivity helps explain both sildenafil's primary mechanism and some effects that emerge when concentrations are high enough for interaction with less-preferred PDE targets.
The best-established sildenafil example is PDE6. Sildenafil is only about 10-fold more potent at PDE5 than PDE6, and current labeling identifies this relatively narrow selectivity margin as the likely basis for abnormalities in color vision observed with higher doses or plasma concentrations.
The PDE3 comparison illustrates the opposite situation. Sildenafil is approximately 4,000-fold more selective for PDE5 than PDE3, an enzyme involved in cardiac contractility.
These examples also show why selectivity should not be reduced to a single statement that sildenafil is 'specific' for PDE5. It is highly selective for PDE5 relative to most PDE families, but not absolutely exclusive.
| Selectivity Observation | Interpretation |
|---|---|
| PDE5 is the preferred target | Explains the primary pharmacodynamic mechanism |
| Only ~10-fold separation from PDE6 | Provides mechanistic context for color-vision effects |
| ~4,000-fold separation from PDE3 | Shows very strong preference over a PDE involved in cardiac contractility |
| Selectivity is not exclusivity | Other PDE targets can become pharmacologically relevant depending on potency and exposure |
| In-vitro ratio | Should not be interpreted as a clinical dose ratio |
Knowing that sildenafil inhibits PDE5 does not establish how much response a particular person will experience. Target inhibition is only one layer in the complete PK-PD system.
Clinical response depends on sildenafil exposure, physiological pathway activation, tissue context, target availability and downstream signaling. In ED specifically, upstream sexual stimulation and nitric oxide release remain necessary components of the labeled mechanism.
Likewise, an in-vitro IC50 or PDE selectivity ratio is a mechanistic measurement rather than a direct prediction of effectiveness, adverse effects or the correct dose for an individual.
| Observation | What It Supports | What It Does Not Establish |
|---|---|---|
| PDE5 inhibition | Primary molecular mechanism | Individual clinical response |
| IC50 | Experimental inhibitory potency | A universal therapeutic plasma threshold |
| PDE selectivity ratio | Relative in-vitro target preference | Clinical dose conversion between PDE targets |
| Higher exposure | Greater opportunity for target interaction | Guaranteed proportional response |
| NO–cGMP pathway activation | Physiological context for PDE5 inhibition | Response magnitude by itself |
Sildenafil PDE5 inhibition can be summarized at three target-level layers: PDE5 hydrolyzes cGMP, sildenafil competitively inhibits PDE5, and the drug is much more potent at PDE5 than at most related phosphodiesterases.
The important exception in the selectivity profile is PDE6, where the separation is only about tenfold. By contrast, selectivity over PDE3 is approximately 4,000-fold, and potency at many other PDE families is more than 700-fold lower than at PDE5.
Those target-level facts explain the molecular mechanism without replacing the broader signaling and response framework. Detailed pathway biology remains on the NO–cGMP pathway page, and integrated pharmacodynamics remains on the sildenafil pharmacodynamics page.
| Research Question | Best Answer |
|---|---|
| What is sildenafil's main molecular target? | cGMP-specific PDE5 |
| What does PDE5 do? | Hydrolyzes cGMP and limits cGMP signaling |
| How does sildenafil inhibit it? | Competitive inhibition of PDE5 catalytic activity |
| How potent is sildenafil in classic in-vitro PDE5 testing? | IC50 approximately 3.5 nM under the reported assay conditions |
| Which related PDE has the narrowest major selectivity margin? | PDE6 at approximately 10-fold |
| Why is PDE6 relevant? | It participates in retinal phototransduction |
| How selective is sildenafil over PDE3? | Approximately 4,000-fold |
| Does target inhibition alone predict clinical response? | No |
Sildenafil primarily inhibits phosphodiesterase type 5, or PDE5, a cGMP-specific enzyme that hydrolyzes cGMP and helps terminate cGMP-dependent signaling.
Yes. Classic in-vitro pharmacology characterized sildenafil as a potent competitive PDE5 inhibitor, with an IC50 of approximately 3.5 nM under the assay conditions used in that research.
Current U.S. labeling reports approximately 10-fold selectivity for PDE5 over PDE6, greater than 80-fold over PDE1, greater than 700-fold over several other PDE families and approximately 4,000-fold selectivity over PDE3.
PDE6 is involved in retinal phototransduction, and sildenafil has a relatively narrow approximately 10-fold PDE5-versus-PDE6 selectivity margin. Current labeling identifies this lower selectivity as the likely basis for color-vision abnormalities seen with higher doses or plasma levels.
PDE3 is involved in control of cardiac contractility. Sildenafil is approximately 4,000-fold more selective for PDE5 than PDE3, providing a large in-vitro target-selectivity margin.
Yes. N-desmethyl sildenafil has a phosphodiesterase selectivity profile similar to the parent drug and approximately 50% of parent sildenafil's in-vitro PDE5 potency.